US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

29.14

+0.43071.50%

Post-market: 29.170.0298+0.10%16:10 EDT

Volume:1K

Turnover:29.61K

Market Cap:2.62M

PE:- -

High:29.31

Open:29.30

Low:29.14

Close:28.71

52wk High:29.31

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:1.28

T/O Rate:1.12%

Dividend:0.92

Dividend Rate:3.15%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Immunocore achieves target patient enrollment in TEBE-AM clinical trial

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Scholar Rock announces FDA approval of isembyld

Pharming wins FDA nod to extend Joenja use to younger APDS children

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Tech Giant Pours Record €13 Billion into Nordic AI Hub

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NVIB/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":29.1392,"timestamp":1790971200000,"preClose":28.7085,"halted":0,"volume":1011,"hourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"delay":0,"changeRate":0.015002525384467948,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.4307,"latestTime":"10-02 16:00:00 EDT","open":29.3,"high":29.31,"low":29.1392,"amount":29609,"amplitude":0.005949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.7085,"nav":29.11,"aum":2619962.27,"dividendRate":0.031511,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"volumeRatio":1.282669145427962},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.282669145427962,"shares":90001,"dividePrice":0.9182,"high":29.31,"amplitude":0.005949,"preClose":28.7085,"low":29.1392,"week52Low":24.54,"pbRate":"--","week52High":29.31,"institutionHeld":0,"latestPrice":29.1392,"eps":0,"divideRate":0.031511,"volume":1011,"delay":0,"ttmEps":0,"open":29.3,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.0966,"twentyDayClose":28.4889},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","XLVX","BK4585","PINK","LFSC","IEIH","GNMX","MRNY","FRTY","BK4588","GDOC","PSCH","BMED","BBP","IBB","MEDI","LABU","MRNX","IDNA","IYH","SYNB","NVIB","TECB","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","XLVX","MRNX","PINK","TBXU","SYNB","GNMX","GDOC","THNR","PSCH","BBP","MEDI","LABU","IDNA","BMED","BK4585","BK4588","MRNY","BK4139","IBRN","SRRK","FRTY","LFSC","IBB","IYH","NVIB","RSPH","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668170","title":"Immunocore achieves target patient enrollment in TEBE-AM clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668170?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:20","pubTimestamp":1789384814,"startTime":"0","endTime":"0","summary":"Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","GDOC","IDNA","NVIB","BK4139","IMCR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576635","title":"Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576635","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576635?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:19","pubTimestamp":1789341541,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing pre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EINC","IE00BMG7P694.USD","TPYP","IE000SL1IH01.SGD","IE00BMG7P926.USD","IE00BD4GTT62.SGD","IE00BMG7P587.USD","IE00BMG7P702.HKD","MLPX","TRP","IE00BD4GTW91.USD","IE00BMG7P819.SGD","XBIX","IE000WXP2NQ0.USD","BK4144","IE00BD4GTV84.USD","IE000HOSIQF4.USD","BBC","NVIB","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635880","title":"Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635880?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:56","pubTimestamp":1789340203,"startTime":"0","endTime":"0","summary":"Noxopharm Ltd. ( ($AU:NOX) ) has provided an update. Australian biotech Noxopharm is advancing its lead topical therapy SOF-SKN, developed from its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","SOF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4179","MRNY","TECB","FRTY","MRNX","IBB","MEDI","BK4139","IDNA","NVIB","TBXU","PINK","BMED","FET","GNMX","GDOC","SYNB","BBP","BK4588","LABU","TLX","LFSC","IYH","RSPH","BK4585","PSCH","IEIH","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBRN","IBB","LABU","IDNA","RSPH","TECB","SRRK","IYH","MRNY","BK4585","NVIB","BMED","FRTY","BBP","XLVX","TBXU","THNR","MRNX","BK4588","PINK","LFSC","PSCH","SYNB","MEDI","GNMX","IEIH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","MRNX","GDOC","IYH","FRTY","IEIH","LFSC","TECB","MEDI","NVIB","TBXU","LABU","SYNB","RSPH","IDNA","GNMX","PINK","PSCH","MRNY","BMED","BK4588","BBP","XLVX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666111665","title":"The Race for the Next Big Weight-Loss Drug is On-and China Wants In","url":"https://stock-news.laohu8.com/highlight/detail?id=2666111665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666111665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:00","pubTimestamp":1789084800,"startTime":"0","endTime":"0","summary":"SHANGHAI-Chinese biotech companies, rapidly evolving from manufacturers of low-end generic drugs to serious competitors to American pharma giants, are training their sights on one of the most lucrativ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BMED","HYLG","NVIB","XBIX","MEDX","JDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518847","title":"Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518847?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:21","pubTimestamp":1789064460,"startTime":"0","endTime":"0","summary":"Investors poured fresh capital into applied AI and precision biotech this week, with Gimlet Labs raising $300M at a $3B valuation and Encoded Thera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TACU","VTHR","QTOC","AIPO","BK4007","LENZ","TSPA","ARTY","BK4539","CHAT","NVIB","BK4139","XBIX","CDIG","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","IDNA","GDOC","MEDX","PSIL","NVIB","OPTH","HYLG","BBC","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599595","title":"IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599595","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599595?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047000,"startTime":"0","endTime":"0","summary":"Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359640/0/en/imunon-enters-cooperative-research-and-development-agreement-with-national-cancer-institute-to-advance-clinical-development-of-imnn-001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4139","IDNA","MEDX","NCI","GDOC","BK4202","IMNN","NHLD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4561","LENZ","BK4539","MEDX","UBCP","ASO","BK4211","GDOC","NVIB","CMP","IDNA","BK4007","BK4139","BK4168","BK4200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK4097","NVIB","HYLG","IMNN","PRGS","LU2065732104.USD","BK4139","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LU1861220207.SGD","IDNA","BK4195","BK4539","MEDX","GDOC","BK4139","NVIB","LU2360107671.USD","AX","LU1861217088.USD","BK4211","PRQR","HYLG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538313","title":"Bayer initiates Phase II study of BAY 3670549 in patients with AFib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538313","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538313?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954315,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BAYRY","BAY","BK4007","NVIB","GDOC","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDNA","CCR","SLE","HYLG","FATE","GDOC","MEDX","BMED","BK4077","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","IDNA","LABU","MEDX","HYLG","BK4585","BK4588","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INN","BK4181","DBB","IDNA","GDOC","BK4218","HYLG","SAT","NVIB","MEDX","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155106466","title":"Tech Giant Pours Record €13 Billion into Nordic AI Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1155106466","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155106466?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:25","pubTimestamp":1788945959,"startTime":"0","endTime":"0","summary":"Search engine behemoth Alphabet is making its largest-ever European commitment, funneling €13 billion (approximately $15.1 billion USD) into Finnish artificial intelligence infrastructure. This...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMZW","IE00B3S45H60.SGD","LU2764262908.HKD","TRUC","LU2381873111.SGD","LU0211328371.USD","LU1201861165.SGD","LU1674673691.USD","TIME","LU2077746001.SGD","LU2111349929.HKD","LU0342679015.USD","IE00BQXX3D17.EUR","LU0868494708.USD","LU1043141396.HKD","LU1791710400.SGD","LU0742534661.SGD","LU2168564065.EUR","LU0557290698.USD","BK4543","LU2463028550.USD","BK4554","IE00BWXC8680.SGD","LU0985489474.SGD","IE00BDCRKT87.USD","LU0094547139.USD","THMZ","LU2237443978.SGD","FXL","LU1280957306.USD","LU2236285917.USD","IE0009356076.USD","LU2347655073.USD","GOOW","LU2023250330.USD","GOOP","IE00B5TLWC47.USD","LU2471134879.HKD","LU2087621335.USD","LU0784384876.USD","ORCZ","SNPE","LU1244550494.USD","LU1066051498.USD","LU1670756490.USD","IE00BFSS7M15.SGD","LU2471134796.USD","LU0061474705.USD","TEK","SG9999014542.SGD","LU1046421795.USD","LU0052756011.USD","LU0215105999.USD","LU2471134523.USD","LU0889566641.SGD","SG9999018857.SGD","LU2097344431.USD","LU1202635105.USD","LU1127390331.HKD","LU0642271901.SGD","LU0661504455.SGD","LU1267930730.SGD","BK4588","LU2552382132.HKD","LU0965508806.USD","LU0006306889.USD","LU0788109477.HKD","LU2237443549.SGD","LU0786609619.USD","IE00BDRTCR15.USD","ORCX","LU0511384066.AUD","LU0689472784.USD","LU2462157665.USD","LU0256863811.USD","LU0124676726.USD","IE00BZ1G4Q59.USD","LU1979441026.SGD","USMD","LU0107464264.USD","LU0149725797.USD","LU0965509010.AUD","AVGX","LU2360032135.SGD","AMZG","LU0787776722.HKD","BK4527","GGLL","LU1196500208.SGD","LU1323610961.USD","LU2750360997.AUD","EFIV","LU0648000940.SGD","CRTC","LU0057025933.USD","LU0316494557.USD","LU2404859741.USD","LU1868837300.USD","LU1880398554.USD","LU1303367103.USD","LU1989764748.USD","LU2456880835.USD","LU2265009873.SGD","LU0175139822.USD","LU0689626769.HKD","LU1232071149.USD","LU2237443895.HKD","SMCC","LU1066051811.HKD","LU1400636657.SGD","BK4507","ALAI","LU0345774391.USD","LU1116320737.USD","IE00B775H168.HKD","LU1400636491.USD","SG9999000418.SGD","LU0203345920.USD","LU0477156953.USD","LU2404859667.USD","IE00BJJMRX11.SGD","USJW.SI","LU2133065610.SGD","LU2286300806.USD","LU0097036916.USD","HK0000819398.USD","LU2065170008.USD","AIPI","GB00B4LPDJ14.GBP","LU0353189680.USD","JGRO","LU0234570918.USD","LU1430594728.SGD","LU1548497426.USD","LU1815336760.USD","LU1084165304.USD","AVGW","LU2430703251.USD","IE0004091025.USD","AMZP","LU1035775433.USD","LU0203201768.USD","BK4533","IE0004086264.USD","LU2361044949.HKD","LU2362541513.USD","LU0964807845.USD","LU2211815571.USD","LU0072461881.USD","LU0889565833.HKD","LU2168564495.EUR","LU2417539215.USD","LU1935043452.HKD","IE00BN8TJ469.HKD","LU1988902786.USD","GOGL","IE0034235295.USD","LU0957808578.USD","IE00BFXG0V08.USD","IE00BJLML261.HKD","LU2237443465.HKD","IE00BFSS8Q28.SGD","IE0005OL40V9.USD","LU2087625088.SGD","LU1645745479.HKD","LU0320765489.SGD","LU2361044865.SGD","LU0211326839.USD","LU0472753341.HKD","TEKY","LU0048573561.USD","LU0949170426.SGD","LU2063271972.USD","IE00B4JS1V06.HKD","LU0345769128.USD","LU0353189763.USD","LU1037948897.HKD","LU1629891620.HKD","AIQD","AVGC","LU1244550577.SGD","LU0061475181.USD","BAY","LU1003077747.HKD","LU1718418525.SGD","XLC","LU1267930227.SGD","LU0157215616.USD","LU0784385170.HKD","LU0130102774.USD","IE0001KFT4U8.USD","LU0444971666.USD","LU0109391861.USD","LU1917777945.USD","LU2362540622.SGD","IE0034235188.USD","LU0957791311.USD","AGIQ","LU0795875169.SGD","LU0251142724.SGD","LU0323591593.USD","BK4077","IVEP","IE00B1BXHZ80.USD","LU1074936037.SGD","LU2168564149.EUR","IE00BFMHRM44.USD","LU0289961442.SGD","LU2275660780.HKD","IE00BJTD4V19.USD","LU1989772840.SGD","HK0000304797.USD","LU1153585028.USD","LU2357627491.SGD","LU0187121727.USD","SG9999014906.USD","GGLS","SKYY","LU2023251221.USD","LU2487616109.SGD","GXPC","LU0426417589.USD","LU0496365809.HKD","LU1267930573.SGD","LU0082616367.USD","LU2102340556.USD","LU2430703178.SGD","LU0823434740.USD","LU1989772923.USD","LU1839511570.USD","LU0096364046.USD","LU1914381329.SGD","LU0251131958.USD","LU1815333072.USD","LU0965509101.SGD","LU2896262040.SGD","IE00B7KXQ091.USD","SG9999014559.SGD","LU1880398471.USD","LU0310800965.SGD","LU2237443382.USD","LU1032955483.USD","LU0109392836.USD","AXTC","LU0708995401.HKD","LU1201861249.SGD","SG9999018865.SGD","LU0251132253.USD","LU2264538146.SGD","TTEQ","BK4503","AVGG","IE00BKDWB100.SGD","LU1551013425.SGD","SG9999014880.SGD","BK4612","LU2462591277.SGD","LU0795875086.SGD","IE00BMPRXQ63.HKD","BK4534","LU2065171311.SGD","LU0162691827.USD","LU1585245621.USD","SG9999014567.USD","LU0203347892.USD","BK4574","LU0068578508.USD","LU0048584097.USD","LU0029864427.USD","LU2462591350.SGD","LU2954938101.SGD","DARP","GPTY","AXTU","LU0130517989.USD","LU0494093205.USD","LU0683600562.USD","LU0210536198.USD","HK0000914686.HKD","LU0466842654.USD","LU1435385759.SGD","LU1935042991.SGD","LU2023250843.SGD","IE00BSNM7G36.USD","QQQG","LU1923623000.USD","LU2168564222.USD","LU2347655156.SGD","FCOM","LU0672654240.SGD","LU0354030438.USD","CMAG","LU0719512351.SGD","IE00BYQQ9H92.USD","SG9999002232.USD","IE00B1XK9C88.USD","LU0267386448.USD","SGXZ81514606.USD","RSPT","LU0708994859.HKD","IE0000B7K699.USD","LU0302445910.USD","BTHM","IE00BN29S564.USD","SMCZ","LU2242650005.HKD","ORAC","LU0079474960.USD","LU0456855351.SGD","LU0308772762.SGD","ORCS","LU0345768740.USD","IE00BJJMRY28.SGD","LU0053666078.USD","QQJG","LU0912757837.SGD","LU2092627202.USD","BK4553","LU0234572021.USD","BK4532","IE00B19Z3B42.SGD","LU1429558221.USD","LU1699723380.USD","BK4538","IE00BKVL7J92.USD","LU0210533765.USD","IE000WAW04H5.SGD","LU0553294199.USD","LU0477156797.USD","LU2054465674.USD","LU2999663052.SGD","LU2756315318.SGD","LU1035773651.USD","LU0820561909.HKD","SPRX","LU0289960550.SGD","LU0143551892.USD","IE00BLSP4452.SGD","LU0792757196.USD","IE00B19Z3581.USD","OGIG","IE00BHPRN162.USD","LU0314106906.USD","LU1261432733.SGD","AZYY","LU2746668461.USD","LU0070302665.USD","ILDR","IE00B19Z8X17.USD","AMZU","LU0345770308.USD","AXTX","LU1923622614.USD","LU0345768153.USD","LU1803068979.SGD","IE0034235303.USD","LU0314104364.USD","LU1935043023.USD","LU2720916845.USD","FDIF","GOOX","WDAI","LU2491050071.SGD","LU2602419157.SGD","LU1069347547.HKD","LU0640476718.USD","LU0724617625.USD","WDCX","BK4592","HK0000914660.USD","LU1366333091.USD","LTL","IE000BZT7R73.USD","LU0130103400.USD","LU0011850046.USD","GTEK","LU1791710582.SGD","BK4587","SGOOGmain","LU2242649171.HKD","EPAI","LU1935043536.SGD","LU2420271590.USD","LU2860962120.EUR","SG9999001077.SGD","SG9999015986.USD","LU0861579265.USD","AMAA","LU2097829019.USD","LU2326559502.SGD","LU0061474960.USD","BK4514","LU2491049909.HKD","LU0994945656.USD","LU2505996681.GBP","LU2065169927.USD","GOOGL","LU1119994496.HKD","IE00BK4W5L77.USD","LU0312595415.SGD","LU2244417387.USD","AIVC","CQTM","LU2213496289.HKD","XDAT","LU2191332357.HKD","LU1267930813.SGD","LU0128525929.USD","LU0158827781.USD","LU0738911758.USD","LU1674673428.USD","AMZZ","IE00B775SV38.USD","LU1670627923.USD","LU2089283258.USD","LU1823568750.SGD","LU1506573853.SGD","LU0784383803.USD","LU0823434583.USD","IE00B19Z9505.USD","SG9999015952.SGD","LU0868494617.USD","IE00BQXX3C00.GBP","LU0198837287.USD","AXTQ","LU0476273544.USD","LU1116320901.HKD","LU2471134952.CNY","TTXU","LU0823421416.USD","LU1037948541.HKD","LU1894683264.USD","LU1803068623.USD","SGXZ99366536.SGD","BK4581","LU1145028129.USD","LU0426412945.USD","BK4602","LU0138981039.USD","LU0265550359.USD","LU1934455863.HKD","LU0128525689.USD","LU2065171402.SGD","LU1235294995.USD","NVIB","LU1868836914.USD","INVN","LU2750360641.GBP","LU0170899867.USD","LU0726765562.USD","IE00BQXX3F31.USD","LU0965509283.SGD","AIS","SG9999015978.USD","LU0133085943.USD","LU1868836591.USD","LU0077335932.USD","LU1868837136.USD","LU1059921491.USD","LU1244550221.USD","XLKI","IE0004445015.USD","LU1670628061.USD","LU2491050154.USD","LU1935042215.USD","LU1989764664.SGD","LU0265550946.USD","DAT","LU0942090050.USD","LU1301847155.USD","AXTL","LU1069344957.HKD","LU2764263203.CNY","BK4585","LU0203202063.USD","LU0345774631.USD","LU1267930490.SGD","LU0949170772.SGD","LU0820561818.USD","LU1691799644.USD","IE00BJTD4N35.SGD","QNXT","LU2357305700.SGD","AVGU","IE00B5949003.HKD","LU0417517546.SGD","LU1496350502.SGD","LU1951198990.SGD","LU1951200564.SGD","LU2764263039.SGD","LU2756315664.SGD","LU0289941410.SGD","LU0225283273.USD","LU0310800379.SGD","SG9999017495.SGD","LU0395794307.EUR","LU0276348264.USD","LU2505996509.AUD","LU1720051017.SGD","LU1894683348.USD","LU0174119429.USD","LU1066053197.SGD","LU2023250504.SGD","SG9999015945.SGD","LU0690374961.EUR","GOOG","LU1221951046.USD","LU1974910355.USD","LU0310799852.SGD","LU0238689110.USD","LU2746668974.SGD","LU2552382215.SGD","IE00BLSP4239.USD","LU2125909593.SGD","LU1804176565.USD","LU1852331112.SGD","LU1043141123.HKD","LU0444973449.USD","LU2125154935.USD","ORCU","LU2089284900.SGD","AMZY","SG9999014898.SGD","LU1868836757.USD","LU0127658192.USD","GOU","LU1934455277.USD","LU0820562030.AUD","AMZO","LU0256863902.USD","LU1633808545.USD","LU0345769631.USD","LU1720051108.HKD","LU1814569148.SGD","LU0289739343.SGD","LU0158827948.USD","LU2361045086.USD","METV","LU1316542783.SGD","SGXZ31699556.SGD","LU1551013342.USD","BK4566","GOOY","IE0004445239.USD","BK4573","LU0859254822.USD","LU2360106780.USD","LU1400636574.HKD","LU0943347566.SGD","LU1732799900.SGD","HK0000304805.HKD","LU0072462426.USD","DRAI","LU0784385840.USD","LU1366192091.USD","NTAL","LU0878866978.SGD","LU2592432038.USD","LU0354030511.USD","LU2092937148.SGD","LU0211331839.USD","LU2125154778.USD","LU0433182093.SGD","QBIG","LU0080751232.USD","LU1144417596.USD","AMZD","WDCC","IE000MB6IJN5.SGD","LU2237443622.USD","MQQQ","LU0690374615.EUR","LU0545039389.USD","LU1496350171.SGD","LU1935042488.USD","LU0823421333.USD","LU2461242641.AUD","LU2403377893.USD","BK4576","LU2271345857.HKD","AVS","LU2362541273.HKD","LU2552382058.USD","LU0211327993.USD","SMCX","IE00BMPRXR70.SGD","BK4561","LU1732800096.USD","XQQI","LU2430703095.HKD","IE00BKPKM429.USD","IE0002270589.USD","IE00BD6J9T35.USD","BK4550","BK4579","SMCL","SGXZ80539844.SGD","SG9999002224.SGD","LU2097344357.USD","LU0069063385.USD","IE00BK4W5M84.HKD","LU0096362180.USD","AVL","IE000F7OJYX1.SGD","LU2637965513.SGD","QMNV","IE00B19Z8W00.USD","IE00BMPRXN33.USD","LU1642822529.SGD","LU2433249047.HKD","LU2168563687.JPY","LU0345770993.USD","CNEQ","LU1221951129.SGD","LU2237438978.USD","SG9999015358.SGD","BK4525","LU2458330243.SGD","LU0106261372.USD","LU2247934214.USD","SMCY","IE00BYXW3230.USD","LU0154236417.USD","LU0985320562.USD","LU0648001328.SGD","LU0208291251.USD","QXQ","LU0320765059.SGD","BK4598","LU0210528500.USD","FRWD","LU0980610538.SGD","LU2458330169.SGD","SG9999015341.SGD","HK0000532082.HKD","LU1064131342.USD","LU0130518102.USD","LU1121112475.USD","LU1571399168.USD","LU0348723411.USD","LU1778281490.HKD","LU2250418816.HKD","SGXZ44715902.SGD","LU0882574139.USD","IE000SO60NU8.SGD","IE00BZ199S13.USD","LU2028103732.USD","LU1489326972.SGD","LU0070217475.USD","IE00B7SZLL34.SGD","GOOL","LU1066051225.USD","LU0211326755.USD","SGXZ51526630.SGD","SMYY","VOX","LU2452424414.USD","LU0056508442.USD","LU0528227936.USD","LU1934455194.USD","LU2108987350.USD","LU2125909247.SGD","BK4548","GB00B4QBRK32.GBP","LU2106854487.HKD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU2543165471.USD","SG9999014575.USD","LU2098885051.SGD","SG9999014914.USD","LU0976567544.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}